Please wait a minute...
European Journal of Gynaecological Oncology  2020, Vol. 41 Issue (5): 824-827    DOI: 10.31083/j.ejgo.2020.05.5468
Case Report Previous articles | Next articles
Hypercalcemia associated with primary mucinous ovarian tumor followed by pseudomyxoma peritonei can be fatal: a case report
Jisu Yeom1, Seulki Lee1, Youngsun Kim1, *()
1Department of Obstetrics and Gynecology, Kyung Hee Medical Center, College of Medicine, Kyung Hee university, Seoul, Republic of Korea
Download:  PDF(2721KB)  ( 179 ) Full text   ( 10 )
Export:  BibTeX | EndNote (RIS)      
Abstract  
Hypercalcemia is a common complication of malignancy, occurring in up to 30% of patients. The development of hypercalcemia in patients with cancer portends a worse prognosis, with patients more likely to have advanced disease and decreased survival rates. Mucinous neoplasms of the ovary account for 10%–15% of ovarian neoplasms. They may be benign, borderline, or malignant. The majority are benign or borderline, accounting for 80% and 16%–17%, respectively. Pseudomyxoma peritonei (PMP) is a rare disease. It refers that PMP is the accumulation of mucin in the abdominal or pelvic cavity derived from associated mucinous tumor usually from the appendix, but also associated with ovarian mucinous tumors. Herein, we report a case of hypercalcemia associated with primary mucinous ovarian tumor followed by PMP that had fatal consequences.
Key words:  Hypercalcemia      Mucinous ovarian tumor      Pseudomyxoma peritonei     
Submitted:  05 February 2020      Accepted:  01 April 2020      Published:  15 October 2020     
*Corresponding Author(s):  YOUNGSUN KIM     E-mail:  chacha0725@naver.com

Cite this article: 

Jisu Yeom, Seulki Lee, Youngsun Kim. Hypercalcemia associated with primary mucinous ovarian tumor followed by pseudomyxoma peritonei can be fatal: a case report. European Journal of Gynaecological Oncology, 2020, 41(5): 824-827.

URL: 

https://ejgo.imrpress.com/EN/10.31083/j.ejgo.2020.05.5468     OR     https://ejgo.imrpress.com/EN/Y2020/V41/I5/824

[1] Tomoko Matsuzono, Li Wai Hon, Chan Yuk May May. Is appendectomy a must for borderline and invasive mucinous ovarian tumour?[J]. European Journal of Gynaecological Oncology, 2020, 41(3): 444-448.
[2] L. N. Abaid, N. Zekry, A. Ronaghi, R. C. Kankus, B. H. Goldstein. Primary management of an extremely large, invasive mucinous ovarian adenocarcinoma: a case report[J]. European Journal of Gynaecological Oncology, 2019, 40(6): 1044-1046.
[3] Y. Yamamoto, Y. Kunimi, A. Wakikawa, A. Ueno, R. Nagai, J. Komatsu, S. Minami, K. Hayashi. Comparison of benign, borderline, and malignant mucinous ovarian tumors[J]. European Journal of Gynaecological Oncology, 2018, 39(5): 751-754.
[4] Hee Yong Kang, Su-Mi Lee, Seung-Beom Kim, Jong-Man Kang. Acute hyperglycemia following intraperitoneal irrigation with 5% dextrose in a patient with pseudomyxoma peritonei. A case report[J]. European Journal of Gynaecological Oncology, 2018, 39(4): 676-678.
[5] F. Lai-Tiong. Ovarian mucinous tumor with anaplastic carcinoma and sarcoma-like mural nodule: about a difficult case[J]. European Journal of Gynaecological Oncology, 2017, 38(4): 618-620.
[1] Eli M. Roth, Michael H. Davidson. PCSK9 Inhibitors: Mechanism of Action, Efficacy, and Safety[J]. Reviews in Cardiovascular Medicine, 2018, 19(S1): 31 -46 .
[2] Akanksha Agrawal, Deepanshu Jain, Pradhum Ram, Jorge Luis Penalver Leon, Janani Rangaswami. Anticoagulation for intra-cardiac thrombi in peripartum cardiomyopathy: A review of the literature[J]. Reviews in Cardiovascular Medicine, 2019, 20(2): 53 -58 .
[3] B. Soltész, J. Lukács, A. Penyige, R. Póka, B. Nagy. Determination of miR-193b rs30236 single nucleotide polymorphism in ovarian cancer patients[J]. European Journal of Gynaecological Oncology, 2019, 40(4): 547 -550 .
[4] Y. Li, C. Li, N. Li, L. Jiang, W. Yang, Y. Wang, B. Wu, C. Shi, Z. Zhu. RNAi silenced NUP88 gene suppresses growth and invasiveness of human breast cancer cell line MCF-7[J]. European Journal of Gynaecological Oncology, 2019, 40(4): 634 -639 .
[5] M. Pakiž, L. Lukman, N. Kozar. Patients' and physicians' expectations differ significantly during the follow-up period after completion of primary treatment of gynecological or breast cancer[J]. European Journal of Gynaecological Oncology, 2019, 40(5): 781 -786 .
[6] T. Tomimatsu, S. Mabuchi, T. Tsuboyama, Y. Hori, S. Sekine, T. Kimura. Malignant transformation of uterine leiomyoma: suggested by clinical, imaging, histological, and genetic findings[J]. European Journal of Gynaecological Oncology, 2019, 40(5): 879 -882 .
[7] Z. Protrka, P. Arsenijevic, N. Jovic, S. Zivanovic, J. Djuric, A. Dimitrijevic. A case of uterine torsion in term pregnancy associated with placental abruption and intrauterine fetal demise[J]. Clinical and Experimental Obstetrics & Gynecology, 2018, 45(2): 287 -289 .
[8] T. Ueno, H. Yabushita, K. Iwasaki, A. Wakatsuki. Role of adiponectin and leptin in non-diabetic, non-obese patients with endometrial cancer[J]. European Journal of Gynaecological Oncology, 2018, 39(2): 199 -204 .
[9] P. Pimsi, W. Santimaleeworagun, S. Therasakvichya, N. Saengsukkasemsak, A. Laocharoenkeat. The incidence and risk factors of severe neutropenia and febrile neutropenia due to chemotherapy among gynecologic cancer patients in Thailand[J]. European Journal of Gynaecological Oncology, 2018, 39(2): 242 -246 .
[10] F. Lai-Tiong. Dermatomyositis revealing a 18-year breast cancer recurrence[J]. European Journal of Gynaecological Oncology, 2018, 39(2): 292 -293 .